ALT Altimmune
- 7.370
- +0.150+2.08%
- 7.160
- -0.210-2.85%
Altimmune News
Buy Rating Justified: Altimmune's Pemvidutide Shows Best-in-Class Potential for Obesity and MASH
Daily rights tracking | WSB concept stocks are once again in a rush of emptying! AMC and GME options transactions surged, and a single call earned more than 55 times the option premium
Alibaba rose nearly 6% overnight and will release pre-market results for today's US stocks. Overnight options transactions increased about 2 times month-on-month to 560,000, and the stock continued to have a high bullish ratio, rising from 69.9% to 73.5%. This Friday, the call with an exercise price of 85 US dollars topped the list with nearly 25,000 transactions, with nearly 24,000 unclosed positions.
Altimmune First Quarter 2024 Earnings: US$0.34 Loss per Share (Vs US$0.40 Loss in 1Q 2023)
Altimmune, Inc. (NASDAQ:ALT) Q1 2024 Earnings Call Transcript
Altimmune Inc (ALT) Reports Q1 2024 Financials: A Detailed Review
Buy Rating Affirmed for Altimmune on Pemvidutide's Potential and Strategic Advancements
Altimmune Is Maintained at Market Outperform by JMP Securities
Altimmune Is Maintained at Market Outperform by JMP Securities
J.P. Morgan Securities: Maintaining the Altimmune (ALT.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $25.00 to $24.00.
J.P. Morgan Securities: Maintaining the Altimmune (ALT.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $25.00 to $24.00.
JMP Securities Maintains Market Outperform on Altimmune, Lowers Price Target to $24
JMP Securities analyst Jonathan Wolleben maintains Altimmune (NASDAQ:ALT) with a Market Outperform and lowers the price target from $25 to $24.
Analysts Offer Insights on Healthcare Companies: Altimmune (ALT), Evolent Health (EVH) and Cormedix (CRMD)
Earnings Call Summary | Altimmune(ALT.US) Q1 2024 Earnings Conference
The following is a summary of the Altimmune, Inc. (ALT) Q1 2024 Earnings Call Transcript:Financial Performance:Altimmune reported cash and cash equivalents of approximately $182.1 million at Q1 2024 e
Altimmune | 10-Q: Quarterly report
Earnings Flash (ALT) ALTIMMUNE Reports Q1 Revenue $5,000
07:03 AM EDT, 05/09/2024 (MT Newswires) -- Earnings Flash (ALT) ALTIMMUNE Reports Q1 Revenue $5,000
Altimmune 1Q Loss/Shr 34c >ALT
Altimmune 1Q Loss/Shr 34c >ALT
Altimmune Q1 2024 Earnings Preview
Is the “Nolly” monopoly myth changing? Pharmaceutical companies frequently introduce new drugs, and “weight loss duos” face challenges
Novo Nordisk and Eli Lilly's dominance in the emerging diet medicine market could eventually be threatened by strong rivals.
Jim Cramer Calls Nutanix 'The Perfect Enterprise Software Company For The Moment'
On CNBC's "Mad Money Lightning Round," Jim Cramer described Quanta Services (NYSE:PWR) as "so good" and a "terrific" company.On May 2, Quanta Services posted better-than-expected quarterly results."I
Altimmune to Participate at Two Upcoming Investor Conferences
GAITHERSBURG, Md., May 07, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will participate and be
Altimmune to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024
GAITHERSBURG, Md., May 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2024 financial results on Thursday,
Altimmune to Participate at Two Upcoming Conferences
GAITHERSBURG, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, will present on
Analysis
Price Target
No Data
